Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)

Q: What does CUSIP 29337E102 represent in this 13F holders report?

CUSIP 29337E102 is the security identifier for ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q3 2025?

132 institutional investors reported ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q3 2025. Use the holders table for investor-level position and value details.

CUSIP: 29337E102

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 58,923,077
Total 13F shares: 59,389,507
Share change: -50,833
Total reported value: $1,215,687,864
Price per share: $20.47
Number of holders: 132
Value change: -$296,366
Number of buys: 77
Number of sells: 42

Quarterly Holders Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2025
Previous quarter: Q2 2025

Recent filing periods for CUSIP 29337E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	3/4/5 13D/G 13F	Director, 10%+ Owner · Company	13% from 13D/G	7,663,349	$169,666,547	—	16 May 2024	3/4/5 13D/G 13F
FMR LLC	13D/G 13F	Company	13%	7,870,219	$161,103,383	$0	30 Sep 2025	13D/G 13F
Commodore Capital LP	13D/G 3/4/5 13F	10%+ Owner · Company	9.9%	6,022,957	$135,215,385	$0	30 Jun 2025	13D/G 3/4/5 13F
Fairmount Funds Management LLC	13D/G 13F	Company	6.3%	3,711,444	$83,321,918	+$11,419,103	30 Jun 2025	13D/G 13F
VR Adviser, LLC	13F	Company	6.8%	4,026,331	$80,768,200	—	30 Jun 2025	13F
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	5.4%	3,226,331	$66,042,996	$0	30 Sep 2025	13D/G
David P. Bonita	3/4/5	Director, 10%+ Owner	— mixed-class rows	4,207,568 mixed-class rows	$63,552,894	—	02 Jun 2022	3/4/5
Polar Capital Holdings Plc	13F 13D/G	Company	5.2% from 13D/G	3,050,294	$61,188,898	—	30 Jun 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	5.1% from 13D/G	2,967,134	$59,520,706	—	30 Jun 2025	13F 13D/G
5AM Partners VI, LLC	3/4/5	10%+ Owner	— class O/S missing	3,835,975	$57,156,028	—	14 Feb 2024	3/4/5
VANGUARD GROUP INC	13F	Company	4.1%	2,410,636	$48,357,358	—	30 Jun 2025	13F
New Enterprise Associates 14, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,611,050	$39,518,242	—	05 Apr 2022	3/4/5
Mark Chin	3/4/5	Director	— mixed-class rows	2,352,572 mixed-class rows	$35,477,530	—	02 Jun 2022	3/4/5
JANUS HENDERSON GROUP PLC	13F	Company	2.9%	1,716,412	$34,414,061	—	30 Jun 2025	13F
RA CAPITAL MANAGEMENT, L.P.	3/4/5 13F	Former 10% owner · Company	1.4% from 13F	2,122,465	$32,123,508	—	23 Feb 2023	3/4/5 13F
Braden M. Leonard	3/4/5	10%+ Owner	— class O/S missing	1,997,774	$30,236,309	—	03 Jan 2023	3/4/5
CITADEL ADVISORS LLC	13F	Company	2.5%	1,470,424	$29,496,705	—	30 Jun 2025	13F
Point72 Asset Management, L.P.	13F	Company	2.3%	1,353,078	$27,142,739	—	30 Jun 2025	13F
Blackstone Inc.	13F	Company	2.2%	1,320,592	$26,491,076	—	30 Jun 2025	13F
Capital Research Global Investors	13F	Company	2.2%	1,315,465	$26,388,228	—	30 Jun 2025	13F
Barbara Dalton	3/4/5	Director	— mixed-class rows	1,566,222 mixed-class rows	$23,576,122	—	02 Jun 2022	3/4/5
Woodline Partners LP	13F	Company	1.9%	1,100,657	$22,079,179	—	30 Jun 2025	13F
Novo Holdings A/S	13F	Company	1.8%	1,084,432	$21,753,706	—	30 Jun 2025	13F
Pictet Asset Management Holding SA	13F	Company	1.6%	967,502	$19,408,090	—	30 Jun 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	882,753	$17,710,667	—	30 Jun 2025	13F
STATE STREET CORP	13F	Company	1.4%	816,242	$16,373,815	—	30 Jun 2025	13F
5AM Venture Management, LLC	13F	Company	1.3%	772,477	$15,495,889	—	30 Jun 2025	13F
Rock Springs Capital Management LP	13F	Company	1.2%	701,408	$14,070,244	—	30 Jun 2025	13F
Carl Goldfischer	3/4/5	Director	— mixed-class rows	711,880 mixed-class rows	$10,645,656	—	02 Jun 2022	3/4/5
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.9%	528,250	$10,597,000	—	30 Jun 2025	13F
First Turn Management, LLC	13F	Company	0.87%	509,987	$10,230,339	—	30 Jun 2025	13F
TCG Crossover Management, LLC	13F	Company	0.85%	498,000	$9,989,880	—	30 Jun 2025	13F
Duquesne Family Office LLC	13F	Company	0.79%	463,000	$9,288,000	—	30 Jun 2025	13F
FRANKLIN RESOURCES INC	13F	Company	0.73%	430,240	$8,630,614	—	30 Jun 2025	13F
S.c.a. Candriam	13F	Individual	0.71%	416,650	$8,358,355	—	30 Jun 2025	13F
Affinity Asset Advisors, LLC	13F	Company	0.68%	400,000	$8,024,000	—	30 Jun 2025	13F
Logos Global Management LP	13F	Company	0.59%	350,000	$7,021,000	—	30 Jun 2025	13F
MARSHALL WACE, LLP	13F	Company	0.57%	333,333	$6,686,660	—	30 Jun 2025	13F
NORTHERN TRUST CORP	13F	Company	0.55%	324,628	$6,512,039	—	30 Jun 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.54%	318,449	$6,388,087	—	30 Jun 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.52%	305,660	$6,131,540	—	30 Jun 2025	13F
Ally Bridge Group (NY) LLC	13F	Company	0.48%	281,394	$5,644,764	—	30 Jun 2025	13F
MORGAN STANLEY	13F	Company	0.43%	254,848	$5,112,260	—	30 Jun 2025	13F
Vestal Point Capital, LP	13F	Company	0.42%	250,000	$5,015,000	—	30 Jun 2025	13F
Patient Square Capital LP	13F	Company	0.42%	245,838	$4,931,510	—	30 Jun 2025	13F
Cormorant Asset Management, LP	13F	Company	0.34%	200,000	$4,012,000	—	30 Jun 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.32%	189,505	$3,801,470	—	30 Jun 2025	13F
David M. Mott	3/4/5	Director	— mixed-class rows	237,724 mixed-class rows	$3,469,305	—	02 Jun 2022	3/4/5
HighVista Strategies LLC	13F	Company	0.24%	141,516	$2,838,811	—	30 Jun 2025	13F
UBS Group AG	13F	Company	0.23%	138,280	$2,773,897	—	30 Jun 2025	13F

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q3 2025

As of 30 Sep 2025, Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by 132 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 59,389,507 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, Commodore Capital LP, Fairmount Funds Management LLC, BlackRock, Inc., VR ADVISER, LLC, Polar Capital Holdings Plc, VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, and NOVO HOLDINGS A/S. This page lists 132 institutional shareholders reporting positions in this security for the Q3 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders

123

Q3 2025 holders

132

Holder diff

Investor	Q2 2025 Shares	Q3 2025 Shares	Share Diff	Share Chg %	Q2 2025 Value $	Q3 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.